

4-1-2017

Renin-angiotensin II-aldosterone system blockers and time to renal replacement therapy in children with CKD.

Alison G. Abraham

Aisha Betoko

Jeffrey J. Fadrowski

Christopher Pierce

Susan L. Furth

See next page for additional authors

Follow this and additional works at: <https://scholarlyexchange.childrensmercy.org/papers>

 Part of the [Nephrology Commons](#), and the [Pediatrics Commons](#)

Recommended Citation

Abraham, Alison G.; Betoko, Aisha; Fadrowski, Jeffrey J.; Pierce, Christopher; Furth, Susan L.; Warady, Bradley A.; and Muñoz, Alvaro, "Renin-angiotensin II-aldosterone system blockers and time to renal replacement therapy in children with CKD." (2017). *Manuscripts, Articles, Book Chapters and Other Papers*. 465.

<https://scholarlyexchange.childrensmercy.org/papers/465>

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact bpfannenstiel@cmh.edu.

Creator(s)

Alison G. Abraham, Aisha Betoko, Jeffrey J. Fadrowski, Christopher Pierce, Susan L. Furth, Bradley A. Warady, and Alvaro Muñoz



Published in final edited form as:

Pediatr Nephrol. 2017 April ; 32(4): 643–649. doi:10.1007/s00467-016-3512-4.

Renin-Angiotensin II-Aldosterone System Blockers and Time to Renal Replacement Therapy in Children with CKD

Alison G. Abraham^{1,2}, Aisha Betoko¹, Jeffrey J. Fadrowski², Christopher Pierce¹, Susan L. Furth³, Bradley A. Warady⁴, and Alvaro Muñoz¹

¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

²Johns Hopkins School of Medicine, Baltimore, MD

³Children's Hospital of Philadelphia, Philadelphia, PA

⁴Children's Mercy Hospital, Kansas City, MO

Abstract

Background and objectives—Clinical care decisions to treat chronic kidney disease (CKD) in a growing child must often be made without the benefit of evidence from clinical trials. We used observational data from the Chronic Kidney Disease in Children cohort to estimate the effectiveness of renin-angiotensin II-aldosterone system blockade (RAAS) to delay renal replacement therapy (RRT) in children with CKD.

Methods—851 participants (median age: 11 years, median glomerular filtration rate [GFR]: 52 ml/min/1.73 m², median urine protein to creatinine ratio: 0.35 mg/mg) were included. RAAS use was reported at annual study visits. Both Cox proportional hazards models with time-varying RAAS exposure and Cox marginal structural models (MSM) were used to evaluate the effect of RAAS use on time to RRT. Analyses were adjusted or weighted to control for age, male sex, glomerular diagnosis, GFR, nephrotic range proteinuria, anemia, elevated blood pressure, acidosis, elevated phosphate and elevated potassium.

Results—There were 217 RRT events over 4.1 years median follow-up. At baseline, 472 children (55%) were prevalent RAAS users, who were more likely to be of older age, have a glomerular etiology, have higher urine protein, be anemic, have elevated serum phosphate and potassium, take more medications but less likely to have elevated blood pressure, compared to non-users. RAAS use was found to reduce the risk of RRT by 21% (hazard ratio: 0.79) to 37% (hazard ratio: 0.63) from standard regression adjustment models and MSM models, respectively.

Conclusions—These results support findings in adult studies of a substantial benefit of RAAS use in pediatric CKD patients.

Correspondence: Alison G Abraham, Johns Hopkins Bloomberg School of Medicine, 600 North Wolfe Street, Baltimore MD 21287, Phone: (443) 287-1884, FAX: (410) 955-7587, alison.abraham@jhu.edu.

Compliance with ethical standards

The study design and conduct was approved by the internal review board of each participating center and by an external advisory committee appointed by the National Institutes of Health. Written informed consent/assent was obtained from all participants/families according to local requirements.

COMPETING FINANCIAL INTERESTS

The authors declare that they have no other relevant financial interests.

Keywords

chronic kidney disease; renal replacement therapy; end-stage renal disease; renin angiotensin system; ACE inhibitor; marginal structural model; time-varying covariates

INTRODUCTION

Children represent a small proportion of patients with chronic kidney disease (CKD), a disease estimated to affect 16% of the general U.S. population [1]. Small numbers of children with CKD contribute to the relative paucity of epidemiologic and clinical trial data about progression and optimal treatment of CKD in this patient population. Clinicians are frequently left with little evidence to guide clinical decision making.

Randomized controlled trial data in adults with CKD suggests that renin-angiotensin II-aldosterone system (RAAS) blockers such as angiotensin converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) may slow CKD progression through blood pressure (BP) control and other BP-independent mechanisms [2–5]. There exist no comparable large scale prospective studies in children to assess the efficacy of RAAS blockers in a pediatric CKD setting. Pediatric BP management guidelines for CKD patients recommend that an ARB or ACE-I be used in children for whom treatment with BP-lowering drugs is indicated, irrespective of the level of proteinuria [6]. However the authors acknowledge that, “...limited direct evidence from clinical trials is available with which to assess the efficacy of RAAS in children with CKD.” The often-cited ESCAPE (Effect of Strict Blood Pressure Control and ACE Inhibition on the Progression of Chronic Renal Failure in Pediatric Patients) trial provided participants in both arms of the trial with a standardized dose of an ACE-I, and randomized participants to different levels of blood pressure control achieved with non-RAAS blockers [7]. Results from ESCAPE suggest that intensified BP control slowed the rate of progression to end stage renal disease (ESRD); the effect of ACE-I/ARB use on the outcome was not directly assessed and was assumed to be beneficial.

The dearth of clinical trial data on RAAS blocker efficacy in children with CKD will likely persist as a clinical trial that withholds ACE-I/ARB therapy would likely be considered unethical in the current era. This lack of direct evidence of continued benefit in patients with advanced stages of CKD leaves clinicians with little guidance on ACE-I/ARB therapy continuation for a pediatric patient when an increase in creatinine or serum potassium level is observed. Thus, additional evidence of benefit is needed and assessing the effectiveness of RAAS blockade in observational studies may provide the best available source to inform clinical care decisions and guideline development.

There are unique challenges in quantifying the effect of therapy in an observational study setting. Non-comparability of treated and untreated groups and dynamic use of therapy over time can introduce bias into analytic results. Facing these challenges, we examined the range of potential benefit associated with ACE-I/ARB therapy on time to the endpoint of dialysis or transplant in a large pediatric CKD cohort using both traditional adjustment and marginal structural models.

METHODS

Study sample

The Chronic Kidney Disease in Children (CKiD) study design and cohort characteristics have been described previously [8,9]. In brief, patients 1–16 years of age with an estimated glomerular filtration rate (GFR) of 30 to 90 ml/min per 1.73 m² were enrolled from 54 participating centers in North America.

Ascertainment of ACE-I/ARB use

As part of each annual study visit, children (and/or their parent or guardian) reported all prescribed medications taken by the child in the previous 30 days, including the frequency of each medication dose. Parents or guardians were asked to bring the child's medications to the study visit for confirmation of medications by study staff. Use of ACE-I/ARBs between annual study visits was assumed to be consistent with that reported at the prior visit. Comparisons of ACE-I/ARB discontinuers to continued users was defined based on reported ACE-I/ARB status at the last contributing visit under observation, among those with at least one prior visit at which ACE-I/ARB use was reported.

Covariate measurement and definitions

Kidney function was assessed by determining GFR from plasma iohexol disappearance curves at study entry, one year later, and every other year thereafter using previously reported methods [10]. When GFR was not directly measured, it was estimated using published equations derived from the CKiD population [11]. In either case, GFR was scaled to body surface area (BSA) using the Haycock equation [12]. CKD-related biomarkers were determined at the central CKiD laboratory at the University of Rochester while complete blood count and serum CO₂ were measured locally. Serum creatinine (enzymatic), BUN and renal function panel (serum sodium, potassium, calcium and phosphorus) were analyzed on a Bayer Advia 2400 analyzer (Siemens Diagnostics, Tarrytown NY) and cystatin C was determined by nephelometry (Siemens Diagnostics). Details of the techniques used to measure the first morning urine protein/creatinine ratio (uP/C) have previously been published [13]. BP was determined at each study visit as the average of three auscultatory measurements obtained with an aneroid sphygmomanometer [14]. The CKD diagnoses were reviewed by the members of the CKiD Steering Committee and categorized as either glomerular or non-glomerular etiology. Nephrotic range proteinuria was defined as uP/C > 2.0 mg/mg. Anemia was defined as hemoglobin < 5th percentile using age and sex specific norms [15]. Elevated blood pressure was defined as systolic or diastolic BP > the 90th percentile for age, sex, and height [16] while high normal BP was defined as systolic or diastolic BP between the 50th and 90th percentile. Elevated serum phosphate was defined as > 6.5 mg/dL for children <13 years old and > 4.5 mg/dL for children > 13 years [17]. Elevated serum potassium was defined as > 5.2 mEq/L and acidosis was defined as serum CO₂ < 22 mEq/L [18]. Self-reported annual income was categorized into \$30000, \$30001 to \$75000, and >\$75000. Family size was categorized as 3 or fewer family members versus more than 3 family members. The study also collected self-reported health insurance status (yes/no) and occurrence of an emergency room visit in the past year (yes/no). Past values of covariates were carried forward to fill in missing values.

Definition of Outcome

Development of end-stage kidney disease was considered the initiation of renal replacement therapy (RRT; dialysis or transplant). Time to RRT was defined as the time from the baseline visit of the CKiD study to RRT, loss to follow-up, or October 31, 2015. Deaths, which were rare events in this pediatric cohort, were censored.

Statistical analysis

Cox proportional hazards models were used to evaluate the unadjusted and adjusted associations between time-varying covariate levels and time to RRT. Analyses were adjusted or weighted to control for the confounding effects of age (per year), male sex, glomerular diagnosis, GFR (per ml/min), nephrotic range proteinuria, anemia, elevated blood pressure, elevated potassium, elevated phosphate and acidosis, on the relationship between ACE-I/ARB use and time to RRT. Race was not included as a possible confounder, as race was not associated with ACE-I/ARB use in the current study. Prior work on CKD progression in the CKiD cohort was used to guide selection of potential confounders [19].

In a traditionally adjusted analysis, the time to RRT was regressed on time-varying factors age, GFR, nephrotic range proteinuria, anemia, elevated blood pressure, elevated potassium, elevated phosphate, acidosis, and ACE-I/ARB use, all lagged by one visit relative to the outcome assessment; male sex and glomerular diagnosis status were time-fixed. Exploratory analyses were also done in subgroups defined by age (< 10 years versus >10 years), race (black race versus non-black race), diagnosis (glomerular versus non-glomerular) and duration of reported ACE-I/ARB use while in the study (< 3 years versus ≥ 3 years) to assess the potential for heterogeneity of ACE-I/ARB effect.

In an inverse probability-of-treatment (IPT) weighted marginal structural (MSM) model, the time to RRT was regressed on time-varying ACE-I/ARB use, with stabilized IPT weights [20], used to address confounding by age, GFR, nephrotic range proteinuria, anemia, elevated blood pressure, elevated potassium, elevated phosphate and acidosis. IPT weights were estimated from two pooled logistic models (one for visits prior to initiation of ACE-I/ARB and one for visits after initiation), treating each visit as an observation and including a time-dependent intercept. For visits prior to initiation, the logistic IPT weight models included only age, anemia, nephrotic range proteinuria, elevated blood pressure, elevated potassium, elevated phosphate and acidosis. For visits after initiation, logistic IPT weight models included, in addition to the aforementioned factors, GFR, an indicator for ACE-I/ARB use at the previous visit and a count of the number of past visits on ACE-I/ARBs. IPT weight truncation at the 99th percentile was used to avoid undue influence of extreme weights [21,22]. Inverse probability of censoring (IPC) weights were also estimated and used to control for differential loss to follow-up. IPC weight models included age, GFR, an indicator for ACE-I/ARB use at the previous visit, income level, family size, and emergency room visit occurrence. Weights were estimated and applied using established methods [20]. No subgroup analyses were run using Cox MSM models to avoid possible weight instability.

Analyses were done in SAS version 9.2 (SAS Institute) and in R 2.15.2 [23]. All tests were 2-tailed and a p-value <0.05 was considered statistically significant.

RESULTS

Study Sample

There were 851 participants (588 with a non-glomerular and 263 with a glomerular etiology of CKD) who contributed time and events to the analysis, which represented 96% of the full CKiD cohort. Among those, 217 children experienced RRT, 179 children were lost to follow-up during the period of observation, 6 children died and 449 were administratively censored because they remained RRT free at the end of observation. Participants contributed a median follow-up time of 4.1 years (Interquartile range [IQR]: 2.8, 7.8). Covariate values were missing at 26% of visits; no variable was missing at more than 14% of the visits and clinical variables were missing no more than 5% of the time.

Baseline characteristics by exposure to ACE-I/ARB

At baseline, there were 472 children who were prevalent users of ACE-I/ARBs with 90% on an ACE-I. The most commonly used ACE-I were Enalapril (Vasotec) and Lisinopril (Prinivil, Zestril) accounting for 46% of users each. ACE-I/ARB user groups differed with respect to many characteristics that are predictive of progression [19]. Users were more likely to be of older age, have a glomerular etiology of CKD, have a higher uP/C, be anemic, have elevated serum phosphate, have elevated serum potassium and take more medications; they were less likely to have elevated blood pressure, compared to non-users. (Table 1). Children with glomerular etiology, who comprised a disproportionately large share of ACE-I/ARB users at baseline (45% of users but 31% of the overall cohort), were predominantly diagnosed with: focal segmental glomerulosclerosis (29%), hemolytic uremic syndrome (19%), systemic immunological disease including SLE (14%), chronic glomerulonephritis (8%), familial nephritis (Alport's; 7%), IgA nephropathy (Berger's, 6%), or membranoproliferative glomerulonephritis type I (4%).

Traditionally Adjusted Analysis of ACE-I/ARB and Time to RRT

There was switching that occurred over time with ACE-I/ARB use. The median duration of reported ACE-I/ARB exposure under observation was 3 visits (approximately 3 years) among those with baseline use and 2 visits (approximately 2 years) among initiators who were naïve at baseline. Treating ACE-I/ARB use as time-varying to account for switching and lagging exposure by 1 year, the univariate association with time to RRT was 0.51 (95% CI: 0.39, 0.67), suggesting a strongly protective effect of recent ACE-I/ARB such that recent users had 49% lower hazard of RRT compared to non-users (Table 2). Standard regression adjustment for time-varying demographic and clinical predictors of progression attenuated the effect, however, yielding an estimated hazard ratio of 0.79 (95% CI: 0.59, 1.07), suggesting a weaker non-significant protective effect of recent ACE-I/ARB use on the risk of RRT (21% lower hazard of RRT compared to non-users).

Discontinuation of ACE-I/ARB use and Marginal Structural Models (MSMs)

Table 1 shows a comparison of ACE-I/ARB discontinuers and continuers among children who had prior history of ACE-I/ARB use (N=611 where 472 had baseline use and 139 initiated use under observation) at the last study visit. Discontinuers were more likely to

have a lower GFR, higher uP/C ratio, be anemic, have elevated blood pressure, have elevated phosphate levels and take more medications, but they were less likely to have a glomerular etiology of their kidney disorder. The use of IPT weighting to balance covariate profiles on characteristics that influence both the choice to initiate ACE-I/ARBs and to discontinue ACE-I/ARBs, yielded an estimate of the effect of continuous use of ACE-I/ARB of 0.63 (95% CI: 0.46, 0.87) versus never use in comparable groups, assuming all relevant confounders were measured and appropriately specified (Table 2). This estimate suggests that maintaining children on ACE/ARBs will reduce the hazard of RRT by 37% compared to children never put on ACE-I/ARBs for control of hypertension and proteinuria. Since the model also included IPC weights, the final estimate should also be free of any selection bias resulting from informative dropout under the assumption that measured covariates sufficiently controlled for factors related to differential loss from the study.

Subgroup analyses of ACE-I/ARB and Time to RRT

Using traditionally adjusted analysis of ACE-I/ARB and time to RRT, we found some qualitative differences in the estimated effect of ACE-I/ARB use by subgroup. The adjusted hazard ratios for RRT assessing the effect of recent ACE-I/ARB use among subgroups were as follows: 1.24 (95% CI: 0.48, 3.20) for children 10 years and younger in the cohort versus 0.78 (95% CI: 0.57, 1.07) for children older than 10 years; 0.53 (95% CI: 0.29, 0.98) for children of black race versus 0.87 (95% CI: 0.61, 1.25) for white or other race; 1.36 (95% CI: 0.75, 2.48) for children with glomerular diagnosis versus 0.62 (95% CI: 0.44, 0.89) for children with non-glomerular diagnosis; 0.87 (95% CI: 0.57, 1.35) for children reporting ACE-I/ARB use for less than 3 years versus 0.55 (95% CI: 0.32, 0.96) for children reporting use for 3 or more years.

DISCUSSION

In this analysis, we used two approaches to estimating the effect of ACE-I/ARB therapy on CKD progression in the CKiD observational data. From the time-varying exposure Cox model and the MSM Cox model, we estimated that the use of RAAS blockade reduces the risk of ESRD by 21% (hazard ratio: 0.79) to 37% (hazard ratio: 0.63) in a pediatric CKD cohort. These estimates are consistent with findings in adults. Drawz and Rosenberg et al. [24] suggested that, “The magnitude of these beneficial effects of RAAS blockade is estimated to be about a 20% risk reduction...”, which echoes results from the RENAAL and AASK trials [5,25]. Other adult studies have reported effect sizes in the range of 40% to 70% - for ESRD and serum creatinine doubling endpoints [2,3,26,27].

Our range of estimated risk protection represents uncertainty both with respect to how to best achieve appropriate comparability between treatment groups in an observational study, but also how best to characterize exposure to ACE-I/ARBs given dynamic treatment strategies. The estimate of benefit associated with continuous ACE-I/ARB use from the MSM Cox model may not be reflective of how ACE-I/ARBs are used in clinical practice, and thus may not be achievable. However, there are possible insights from the estimate, which is similar to what one could obtain from a well-run clinical trial.

First, there appears to be benefit associated with continuing use across the full spectrum of disease severity in our study. This has important clinical implications as clinicians caring for children with CKD often observe a reduction in estimated GFR resulting from commencing ACE-I/ARB use, which may prompt them to discontinue the therapy. Though evidence suggests that this phenomenon does not result in long term harm – analyses of RENAAL trial data indicated better long term outcomes in those with an initial fall in GFR [28] – reductions in GFR are concerning and our results suggest that clinicians choose to maintain residual kidney function by discontinuing ACE-I/ARBs. Side effects of ACE-I/ARB use such as hyperkalemia or hypotension were not evident among discontinuers.

Second, the analysis suggests that ACE-I/ARB use is beneficial in a general pediatric CKD population that includes both hypertensive and normotensive participants. In the CKiD cohort, approximately 70% of patients have blood pressure less than the 90th percentile and approximately 20% have blood pressure less than the 50th percentile. The MSM Cox estimate of benefit, which assesses the benefit of continual use in everyone in the cohort, lends support to findings from the Collaborative Study Group that the benefits of ACE-I/ARB use extend beyond blood pressure control [2].

However, our estimate must also be interpreted with caution. The dynamics of treatment decisions can make evaluations of therapy effectiveness challenging in observational data. MSM models try to get around the problem of estimating an effect of a dynamic treatment in the presence of time-varying confounders that are themselves affected by previous treatment, a problem that has been well described [29,30] but may or may not be biasing the standard regression adjustment analysis in the current study. MSM models depend upon the accurate and complete capture of all factors that confound the treatment-outcome relationship, as well as correct specification of the IPT weight model. Many measured and unmeasured factors likely influence clinician decisions and the incorrect or incomplete specification of the IPT model could have resulted in bias in either direction. In point of fact, we found that the clinical covariates in the weighting models were not strongly predictive of ACE-I/ARB initiation or continuation and the continuation/discontinuation groups remained unbalanced suggesting that the MSM Cox estimate is optimistic.

In contrast, the time-varying ACE-I/ARB use status and standard regression adjustment methods addresses the more relevant question of the effect of recent therapy status on the risk of RRT given the reality of dynamic treatment histories. However, adjusting for time-varying factors that are affected by previous ACE-I/ARB treatment could have attenuated the effect estimate if those factors themselves are a means of slowing progression (e.g. reductions in blood pressure achieved by prior use of ACE-I/ARBs). In that case, a 21% reduction in RRT risk would be a conservative estimate.

Exploratory subgroup analyses suggest some differences between strata. It is possible that true differences exist; however it is also possible that these findings are due to chance. Several factors such as black race and glomerular disease represent only 20–30% of the sample and thus there is a danger of spurious results. The width of the confidence intervals in the younger age strata suggests that this estimate may not be robust due to potentially too few events or less ACE-I/ARB use. For assessing duration of ACE-I/ARB use, many

children entering CKiD were in CKD care for years prior to active observation in the study, and thus the history RAAS therapy use is unknown. Therefore the subgroup estimates should only serve to suggest targets for further research.

There are substantial limitations to our analysis that deserve discussion. As the majority of ACE-I/ARB users were on ACE-Is, we could not assess the relative benefits of ACE-I use versus ARB use in this cohort. Further, the current analysis does not suggest a mechanism through which ACE-I/ARBs act to reduce risk, though both elevated blood pressure and proteinuria are established risk factors for progression in children [7,31–33]. The assessment of ACE-I/ARB use is made at each annual visit and therefore, switching in between visits cannot be accounted for in the current analysis. However, after adjusting for GFR and indicators of disease severity, it is unlikely that between visit changes in ACE-I/ARB use would be differential by outcome status. Therefore, switching on and off ACE-I/ARBs in between visits would most likely add random measurement error to the assessment of ACE-I/ARB exposure and attenuate estimates. We could not adjust for clinical site differences in ACE-I/ARB use or outcome risk as most sites contribute relatively few children; thus, confounding by clinical site could have introduced bias into the analysis. We chose to focus on the outcome of time to RRT rather than a composite outcome that incorporated GFR decline to simplify causal interpretation. Future investigation into the effect of ACE-I/ARB use focusing on GFR decline could be done using MSMs for repeated measures data, which have also been developed and described [34]. Finally, our estimates may be biased to the extent that important predictors of either ACE-I/ARB use or time to RRT were not captured or included in the MSM Cox models or standard regression adjusted Cox models, respectively. While predictors of the time to RRT have been well characterized in the CKiD study [19], factors affecting clinical decisions regarding ACE-I/ARB use are less understood and therefore the estimate from the MSM Cox model is most at risk for residual confounding bias.

Our results in a pediatric setting where no direct clinical trial data exist, provide evidence that the benefit of ACE-I/ARB use noted in adult CKD patients extends to children with moderate to severe CKD, providing approximately a 21% to 37% reduction in the risk of RRT.

Acknowledgments

The authors acknowledge the contributions of all investigators and coordinators in the CKiD Study (www.statepi.jhsph.edu/ckid), in addition to all participating patients and their families. Data in this manuscript were collected by the CKiD prospective cohort study with clinical coordinating centers (principal investigators) at Children's Mercy Hospital and the University of Missouri–Kansas City (Bradley A. Warady, MD) and Children's Hospital of Philadelphia (Susan Furth, MD, PhD), Central Biochemistry Laboratory at the University of Rochester Medical Center (George J. Schwartz, MD), and data coordinating center at the Johns Hopkins Bloomberg School of Public Health (Alvaro Muñoz, PhD). The CKiD Study is supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases, with additional funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Heart, Lung and Blood Institute (grants U01-DK-66143, U01-DK-66174, U01DK-082194, and U01-DK-66116).

References

1. U.S. Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases;
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. *N Engl J Med.* 1993; 329:1456–1462. [PubMed: 8413456]
3. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. *Lancet.* 1999; 354:359–364. [PubMed: 10437863]
4. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. *Am J Kidney Dis.* 2000; 35:1155–1165. [PubMed: 10845831]
5. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA.* 2002; 288:2421–2431. [PubMed: 12435255]
6. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney Int Suppl.* 2012; 2:337–414.
7. Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozd D, Fischbach M, Moller K, Wigger M, Peruzzi L, Mehls O, Schaefer F. Strict blood-pressure control and progression of renal failure in children. *N Engl J Med.* 2009; 361:1639–1650. [PubMed: 19846849]
8. Furth SL, Abraham AG, Jerry-Fluker J, Schwartz GJ, Benfield M, Kaskel F, Wong C, Mak RH, Moxey-Mims M, Warady BA. Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. *Clin J Am Soc Nephrol.* 2011; 6:2132–2140. [PubMed: 21841064]
9. Furth SL, Cole SR, Moxey-Mims M, Kaskel F, Mak R, Schwartz G, Wong C, Munoz A, Warady BA. Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. *Clin J Am Soc Nephrol.* 2006; 1:1006–1015.
10. Schwartz GJ, Abraham AG, Furth SL, Warady BA, Munoz A. Optimizing iohexol plasma disappearance curves to measure the glomerular filtration rate in children with chronic kidney disease. *Kidney Int.* 2010; 77:65–71. [PubMed: 19847157]
11. Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA, Furth SL, Muñoz A. Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. *Kidney Int.* 2012; 82:445–453. [PubMed: 22622496]
12. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. *J Pediatr.* 1978; 93:62–66. [PubMed: 650346]
13. Wong CS, Pierce CB, Cole SR, Warady BA, Mak RH, Benador NM, Kaskel F, Furth SL, Schwartz GJ. Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. *Clin J Am Soc Nephrol.* 2009; 4:812–819. [PubMed: 19297612]
14. Flynn JT, Mitsnefes M, Pierce C, Cole SR, Parekh RS, Furth SL, Warady BA. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. *Hypertension.* 2008; 52:631–637. [PubMed: 18725579]
15. Hollowell JG, van Assendelft OW, Gunter EW, Lewis BG, Najjar M, Pfeiffer C. Hematological and iron-related analytes--reference data for persons aged 1 year and over: United States, 1988–94. *Vital Health Stat.* 2004; 11:1–156.

16. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics*. 2004; 114:555–576. [PubMed: 15286277]
17. KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Children with Chronic Kidney Disease. *Am J Kidney Dis*. 2005; 46:S1–S122.
18. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. *Am J Kidney Dis*. 2009; 53:S11–104.
19. Warady BA, Abraham AG, Schwartz GJ, Wong CS, Munoz A, Betoko A, Mitsnefes M, Kaskel F, Greenbaum LA, Mak RH, Flynn J, Moxey-Mims MM, Furth S. Predictors of Rapid Progression of Glomerular and Nonglomerular Kidney Disease in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort. *Am J Kidney Dis*. 2015; 65:878–888. [PubMed: 25799137]
20. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. *Epidemiology*. 2000; 11:561–570. [PubMed: 10955409]
21. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. *Am J Epidemiol*. 2008; 168:656–664. [PubMed: 18682488]
22. Xiao Y, Abrahamowicz M, Moodie EE. Accuracy of conventional and marginal structural Cox model estimators: a simulation study. *Int J Biostat*. 2010; 6 Article 13.
23. R Core Team: A language and environment for statistical computing [Internet]. R Foundation for Statistical Computing; 2012. Available from: [_http://www.R-project.org/_](http://www.R-project.org/)
24. Drawz PE, Rosenberg ME. Slowing progression of chronic kidney disease. *Kidney Int Suppl* 2011. 2013; 3:372–376. [PubMed: 25019022]
25. Brenner BM, Cooper ME, de ZD, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*. 2001; 345:861–86. [PubMed: 11565518]
26. Tokunaga M, Kabashima N, Serino R, Shibata T, Matsumoto M, Miyamoto T, Miyazaki M, Furuno Y, Nakamata J, Fujimoto Y, Takeuchi M, Abe H, Okazaki M, Otsuji Y, Tamura M. Renoprotective effects of telmisartan in patients with advanced chronic kidney disease. *Clin Nephrol*. 2010; 73:139–146. [PubMed: 20129021]
27. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW. Efficacy and safety of benazepril for advanced chronic renal insufficiency. *N Engl J Med*. 2006; 354:131–140. [PubMed: 16407508]
28. Holtkamp FA, de ZD, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, Parving HH, Brenner BM, Shahinfar S, Lambers Heerspink HJ. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. *Kidney Int*. 2011; 80:282–287. [PubMed: 21451458]
29. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. *Epidemiol*. 2000; 11:550–560.
30. Cole SR, Platt RW, Schisterman EF, Chu H, Westreich D, Richardson D, Poole C. Illustrating bias due to conditioning on a collider. *Int J Epidemiol*. 2010; 39:417–420. [PubMed: 19926667]
31. Ardissino G, Testa S, Daccò V, Viganò S, Taioli E, Claris-Appiani A, Procaccio M, Avolio L, Ciofani A, Dello Strologo L, Montini G. Ital Kid Project. Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Data from the Ital Kid Project. *Pediatr Nephrol*. 2004; 19:172–177. [PubMed: 14673629]
32. Wingen AM, Fabian-Bach C, Schaefer F, Mehls O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. *Lancet*. 1997; 349:117–1123.
33. Litwin M. Risk factors for renal failure in children with non-glomerular nephropathies. *Pediatr Nephrol*. 2004; 19:178–186. [PubMed: 14685838]
34. Hernán MA, Brumback BA, Robins JM. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. *Stat Med*. 2002; 21:1689–1709. [PubMed: 12111906]

Table 1

A: Comparison of users and non-users of angiotensin converting enzyme-I/angiotensin receptor blockers (ACE-I/ARBs) at baseline; B: Among those with history of ACE-I/ARB use, comparison of discontinuers and continuers of ACE-I/ARB use at last visit.

Clinical Factors	A: Among cohort (N=851)		B: Among those with history of use (N=611)	
	ACE-I/ARB use at baseline (N=472) ^{a,b}	No ACE-I/ARB use at baseline (N=379) ^{a,b}	Continuer (N=463) ^{a,b}	Discontinuer (N=148) ^{a,b}
<i>Demographics</i>				
Age (years)	12 (9–15)	10 (6–14)	16 (12–18)	15 (13–18)
Male Sex	59%	65%	59%	66%
Black Race	21%	23%	22%	21%
Insurance	97%	98%	97%	97%
Household Income				
\$30,000	35%	34%	32%	36%
\$30001 to \$75000	34%	37%	31%	30%
>\$75,000	31%	29%	37%	34%
Family size 3 members	32%	27%	41%	37%
Emergency room visit in past year	38%	44%	37%	37%
<i>Clinical Characteristics</i>				
Glomerular DX	45%	13%	42%	26%
GFR (mL/min/1.73 m ²)	53 (38–73)	52 (39–70)	47 (33–67)	26 (18–44)
uP/C	0.39 (0.14–1.16)	0.31 (0.11–0.87)	0.45 (0.16–1.49)	1.54 (0.35–3.48)
Anemia	33%	20%	34%	51%
Elevated BP	25%	36%	23%	41%
High normal BP	48%	54%	47%	45%
Elevated Phosphate	16%	10%	19%	44%
Elevated Potassium	10%	5%	9%	9%
Acidosis	54%	49%	70%	78%
# of medications	4 (2–6)	3 (2–5)	4 (2–6)	6 (4–9)

Definitions: uP/C= urine protein/creatinine ratio, anemia= hemoglobin<5th %ile, Elevated BP (blood pressure)=systolic or diastolic BP>90th %ile, high normal BP= systolic or diastolic BP between the 50th and the 90th percentile, Elevated phosphate =serum phosphate> 6.5 mg/dL for children <13 years old and > 4.5 mg/dL for children > 13 years, Elevated potassium= serum potassium > 5.2 mEq/L, acidosis= serum CO₂ < 22 mEq/L.

GFR, glomerular filtration rate

^aValues are medians and interquartile ranges or %

^b**Bold** signifies $P<0.05$ for comparisons between users and non-users in A and between continuers and discontinuers in B from Wilcoxon rank test or Fisher's exact test.

Table 2

Results from Cox proportional hazards models for time to renal replacement therapy (RRT) using time-varying assessment of recent angiotensin converting enzyme-I/angiotensin receptor blocker (ACE-I/ARB) use, unadjusted and adjusted for time-varying covariates and using inverse probability-of-treatment (IPT) weighting to assess the causal effect of continuous use of ACE-I/ARB.

	Hazard Ratio	Confidence Interval
<i>Standard Regression Adjustment</i>		
<i>Unadjusted</i>		
Recent ACE-I/ARB use	0.51	0.39, 0.67
<i>Adjusted</i>		
Recent ACE-I/ARB use	0.79	0.59, 1.07
Age (per 1 year)	1.03	0.99, 1.08
Male Sex	1.05	0.77, 1.41
Glomerular DX	1.56	1.12, 2.17
GFR (per 1 ml/min/1.73 m ²)	0.90	0.89, 0.92
Nephrotic proteinuria	3.57	2.67, 4.78
Anemia	2.06	1.49, 2.84
Elevated BP	1.74	1.32, 2.30
High Phosphate	1.06	0.77, 1.48
High Potassium	1.13	0.78, 1.67
Acidosis	1.05	0.77, 1.43
<i>MSM</i>		
Continuous ACE-I/ARB use (vs. never use)	0.63	0.46, 0.87

Definitions: Nephrotic Proteinuria =urine protein/creatinine ratio>2.0, anemia=hemoglobin <5th %ile, Elevated blood pressure (BP)=systolic or diastolic BP>90th %ile, Elevated phosphate =serum phosphate> 6.5 mg/dL for children <13 years old and > 4.5 mg/dL for children > 13 years, Elevated potassium= serum potassiums > 5.2 mEq/L, acidosis= serum CO₂ < 22 mEq/L.

GFR, glomerular filtration rate

Bold signifies $P < 0.05$